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Abstract
Integrins mediate cell adhesion, migration, and survival by connecting intracellular machinery with the surrounding
extracellular matrix. Previous studies demonstrated the importance of the interaction between b3 integrin and VEGF type 2
receptor (VEGFR2) in VEGF-induced angiogenesis. Here we present in vitro evidence of the direct association between the
cytoplasmic tails (CTs) of b3 and VEGFR2. Specifically, the membrane-proximal motif around
801YLSI in VEGFR2 mediates its
binding to non-phosphorylated b3CT, accommodating an a-helical turn in integrin bound conformation. We also show that
Y
747 phosphorylation of b3 enhances the above interaction. To demonstrate the importance of b3 phosphorylation in
endothelial cell functions, we synthesized b3CT-mimicking Y
747 phosphorylated and unphosphorylated membrane
permeable peptides. We show that a peptide containing phospho-Y
747 but not F
747 significantly inhibits VEGF-induced
signaling and angiogenesis. Moreover, phospho-Y
747 peptide exhibits inhibitory effect only in WT but not in b3 integrin
knock-out or b3 integrin knock-in cells expressing b3 with two tyrosines substituted for phenylalanines, demonstrating its
specificity. Importantly, these peptides have no effect on fibroblast growth factor receptor signaling. Collectively these data
provide novel mechanistic insights into phosphorylation dependent cross-talk between integrin and VEGFR2.
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Introduction
Integrins are a family of transmembrane, heterodimeric
glycoproteins composed of alpha and beta subunits. Each integrin
subunit contains a large extracellular ligand-binding portion, a
single membrane-spanning region, and a short cytoplasmic tail
devoid of any enzymatic activity [1]. A crucial characteristic of all
integrins, and particularly of the two members of the b3 subfamily,
aIIbb3 and avb3, is their ability to become activated upon cell
stimulation due to agonists or growth factors, a process termed
‘inside-out’ signaling. Activated integrins can bind to extracellular
matrix components with high affinity and mediate, through
‘outside-in’ signaling events, many vital cellular processes such as
adhesion, migration, and proliferation [2].
The b subunits’ CTs include two tyrosine phosphorylation sites,
located within NPxY and/or NPxY-like motifs, and are known to
interact with phosphotyrosine binding (PTB) domains of intracel-
lular signaling mediators [3]. These interactions can regulate
integrin activation states differentially. For example, talin serves as
a major activator for non-phosphorylated b3 [4,5], while Dok1
binds to b3 phosphorylated at Y
747 with a higher affinity and thus,
by replacing talin, favors the latent state of the receptor [6]. For
aIIbb3, the biochemical studies suggest that phosphorylation of
both tyrosines (Y
747 and Y
759) is required for the recruitment of
myosin, while phosphorylation of Y
759 alone is sufficient for
interaction with the adapter protein Shc [7,8]. Our recent
structural investigation established the underlying molecular
mechanism behind the interaction between the Shc PTB domain
and tyrosines phosphorylated (Y
747,Y
759) on the b3CT [9]. In
addition, several studies have demonstrated that tyrosine phos-
phorylation of b3 is involved in the regulation of aVb3 integrin-
dependent adhesion, specifically under conditions of cell activa-
tion, and that Y
747F mutation diminished the stimulation-induced
cell adhesion to vitronectin (VN), suggesting that phosphorylation
is necessary for a fully functional avb3 [10,11,12,13]. In addition,
increases in the strength of the avb3-VN interaction were shown to
be dependent on phosphorylation of b3CT [11]. In contrast, avb3
mediated adhesion to fibronectin was shown to be abolished with
increased b3 phosphorylation [14]. Thus, several studies have
demonstrated that tyrosine phosphorylation of b3 integrin might
support different aspects of integrin function. Consequences of
integrin phosphorylation might be further modulated by interac-
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31071tions between integrin and intracellular mediators, the presence of
which depends upon the cell type and the stage of cell adhesion
and spreading.
We have previously demonstrated that avb3 function on the
endothelium depends on its cross-talk with VEGF type receptor
(VEGFR2) [15]. Endothelial cell (EC) stimulation by VEGF
promotes a complex formation between avb3 and VEGFR2, as
well as a conformational change of avb3 to a high affinity state
[16]. VEGF treatment triggers phosphorylation of b3CT on Y
747
and Y
759, which are located within the NPxY and NxxY motifs,
respectively [16,17]. Mutations of these residues to phenylalanines
inhibit the complex formation between VEGFR2 and b3 integrin
and VEGF-induced angiogenic responses [16,17,18]. The rela-
tionship between VEGFR2 and b3 appears to be of a reciprocal
nature, as b3 phosphorylation also leads to enhanced phosphor-
ylation and activation of VEGFR2 [16]. In the presence of normal
b3 expression, the interplay between the two receptors regulates a
number of cellular responses underlying angiogenesis, including
EC adhesion, migration, and formation of endothelial tube
networks [19,20]. Based on our and others’ findings that Y
747F-
Y
759F substitutions diminish adhesion to VN and integrin activity,
we suggest that phosphorylation of these residues must play a
pivotal role in regulation of integrin function [10,11,12,13,16]. In
this study we have defined one of the VEGFR2 binding to b3
motifs corresponding to its membrane-proximal region, we have
shown that tyrosine-phosphorylation promotes the above interac-
tion between b3 and VEGFR2 CTs, and we have proved
physiological significance of this interaction by confirming that
b3 derived Y
747 containing inhibitory peptide diminishes EC tube
formation and angiogenesis. Overall, these data provide novel
molecular and mechanistic insights into phosphorylation depen-
dent cross-talk between integrins and VEGF receptors.
Results
VEGFR2 interacts with b3CT in a phosphorylation
dependent manner
Based on our findings that VEGFR2 regulates integrin
activation and signaling [21] and that b3 tyrosine phosphorylation
is crucial for VEGF-induced tyrosine phosphorylation of VEGFR2
[22], we assessed whether the cytoplasmic portion of VEGFR2
binds directly to b3CT and how tyrosine phosphorylation affects
this interaction. Unlabeled synthetic peptide VpepA (sequence
shown in Materials and Methods), representing the thirty
membrane proximal residues of VEGFR2 cytoplasmic domain,
was titrated into the solution of
15N-labeled b3NP (non-
phosphorylated CT) and
15N-labeled b3MP (mono-Y
747-phos-
phorylated CT). Associated chemical shift perturbations were
monitored (Figure 1a and 1b). Chemical shift changes, plotted as a
function of the residue number in b3CT, are shown in Figure 1c
for b3NP and Figure 1d for b3MP. For non-phosphorylated b3CT,
maximal perturbations occur near the membrane proximal region
(residues
716KLLITIHDRK
725), which might represent the
primary binding site for VEGFR2. However, upon phosphoryla-
tion, in addition to the above region, maximal perturbations were
recorded near the Y
747 phosphorylation site (
744NPLYKEA
750).
This finding represents the second binding site and, possibly,
increased affinity. Although the chemical shift perturbations were
rather modest, they were reproducible and concentration
dependent, and reached saturation at a peptide to protein ratio
of 3 to 1, indicating the low affinity but specific nature of the
observed interaction. Our attempts to calculate the dissociation
constants from these titration series were unsuccessful due to low
solubility and high tendency of the both VpepA and b3CT to
precipitate while forming the complex.
Thus, to further confirm and characterize the weak binding of
VEGFR2-CTderived peptides to non-phosphorylated b3, we have
employed an additional trNOE-based approach. b3CT was
coupled to glutathione S-transferase (GST-b3) and two smaller
VEGFR2 peptides were synthesized (VpepB and VpepC; see
Materials and Methods). TrNOE experiments, the method of
choice for studying ultra-weak ligand-receptor pairs [23], were
performed and the ratios of peptides to GST-b3 were optimized
for the most favorable NOE transfer (appeared to happen at a 50
to 1 ratio). The patterns of additional peaks observed for both
VpepB and VpepC peptides when mixed with GST-b3 were
similar (Figure 1e and 1f, respectively), confirming the interaction
between peptides and GST-b3. However, since more trNOEs were
detected for VpepB, this peptide was chosen for further structural
analysis. The majority of the additional NOE peaks characterize
residues of the region surrounding
801YLSI
804, indicating that this
area assumes a bound conformation upon interaction with b3NP.
It is imperative, however, for the ultra-weak interactions, such as
described above, to confirm their specificity. For this reason, we
performed negative control experiments. There were no additional
peaks in NOESY spectra of GST-VpepB mixtures (data not
shown) and thus we can confidently use this system for structural
characterization of VEGFR2-derived peptides.
While the structural analysis was reported for extracellular
ligand binding [24] and cytoplasmic kinase domains of VEGFR2
[25], no structural information is available regarding the
membrane proximal region of VEGFR2. Accordingly, we
performed structural calculations for VpepB bound to GST-b3.
VpepB exhibits a well defined C-terminal region (
801YLSIV
805),
forming an a-helical turn and an additional loop surrounding two
Gly residues (
792ANGGE
796), whereas the remaining parts are
unstructured. Figure 1g shows a ribbon representation of VpepB
along with ball and stick representation for residues
801YLSI
804.
Figure 1h illuminates backbone superposition of the 15 lowest
energy conformers. Statistics for this ensemble are presented in
Table 1 and the sequential connectivity map is shown in Figure
S1. The NMR data has been deposited to BMRB (access code
18148).
Collectively, our data demonstrate that non-phosphorylated
b3CT interacts with VEGFR2, and this interaction involves the
membrane proximal region within b3CT and
801YLSI
804 motif
within VEGFR2. b3 Y
747 phosphorylation generates an additional
VEGFR2 binding site within the
744NPLYKEA
750 region of
b3CT, which is not susceptible to structural characterization using
the approach employed for the non-phosphorylated b3 (as we were
unable to purify GST-fused mono-Y
747-phosphorylated b3CT)
and awaits the development of novel strategy for further
investigation.
b3CT tyrosine phosphorylation and its consequences in
endothelial cells
Since our recent results [26,27] indicate that phosphorylation of
Y
747 might stabilize the integrin activated state, and the data
presented above show that Y
747 phosphorylation also promotes
b3CT binding to VEGFR2, we next sought to assess the
physiological consequences of b3CT phosphorylation in ECs. To
this end, we utilized a phosphopeptide containing a 16 amino acid
sequence from b3CT encompassing the
744NPLpY
747 motif [12]
(pY747 peptide; Figure 2a). The peptide is expected to compete
with endogenous binding partners for b3MP, including the
VEGFR2 cytoplasmic domain. Previous studies have utilized the
mutations of Y
747 and Y
759 to phenylalanines in order to simulate
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peptide containing nonphosphorylated
744NPLY
747 motif (Y747
peptide, we used a peptide bearing Y
747F mutation (F747 peptide)
as controls in our studies (Figure 2a). The peptides were
conjugated to an HIV-TAT leader sequence to allow delivery
into cells. Indeed, the results of confocal microscopy analysis of
ECs confirmed the uptake and the presence of the peptides within
the cells and, most importantly, on the cell surface (Figure S2).
To assess the requirement of Y
747 phosphorylation of b3 for
integrin-dependent angiogenic responses of ECs, three experi-
mental systems were utilized. During angiogenesis, ECs re-
organize to form a three-dimensional vessel structure [28], and
this could be modeled in vitro in tube formation assays.
Accordingly, tube formation by HUVEC treated with VEGF
was assessed in the presence of b3CT-derived pY747, Y747, or
F747 peptides. As shown in Figure 2b, VEGF-treated HUVEC
formed a robust endothelial network. The tyrosine-phosphorylated
peptide (pY747) inhibited this process, resulting in a disruption of
the network’s structure (Figure 2c). The thickness (Figure 2d), as
well as the tube length (Figure 2f), of endothelial branches formed
in the presence of pY747 peptide was significantly decreased
compared to untreated cells. In contrast, cells treated with control
F747 peptide were able to form a network of endothelial cords as
robust as seen in untreated cells (Figure 2c). Unphosphorylated
Y747 peptide exhibited only a weak or negligible effect (Figure 2c).
In a similar assay, a peptide containing pY
759 sequence from the
second NPxY-like motif of b3 had no inhibitory effect, emphasiz-
ing the unique role of pY
747 residue (Figure 2e). In the aortic ring
assay, pY747 was even more potent. The treatment with pY747,
but not F747 or Y747 peptide, inhibited the sprouting of ECs
stimulated by VEGF by more than 60% (Figure 3a and 3b). Next,
the effect of pY747 peptide on in vivo angiogenesis induced by
VEGF was evaluated. Matrigel containing (or lacking) VEGF and
peptides was injected subcutaneously in C57BL/6 (wild type)
mice. Seven days later, matrigel implants were removed,
sectioned, and blood vessels were stained using CD31 antibody.
The pY747 peptide inhibited VEGF-induced vascularization by
more three-fold, while the control F747 or Y747 peptides had no
effect (Figure 3c and 3d).
The pY747 peptide is predicted to mimic and compete with the
phosphorylated form of endogenous b3 integrin and, therefore, to
also inhibit b3 phosphorylation-dependent responses. Thus, this
peptide should not have any inhibitory activity in mice
characterized by the lack of b3 phosphorylation (b3 knock-out
mice or DiYF knock-in mice [29]), which, in turn, diminishes the
complex formation between b3 and VEGFR2 [16,30]. Indeed, as
shown in Figure 4a and 4b, pY747 phosphopeptide could not
effectively inhibit angiogenesis induced by VEGF in the aortic ring
from b3
2/2 mice, which is corroborated by the experiments with
DiYF knock-in mice (Figure 4c). In addition, pY7474 peptide
inhibition was specific to VEGF as no inhibition of basic fibroblast
growth factor (bFGF) angiogenesis occurred in wild type, b3
2/2,
or DiYF mice (Figure 4c). Furthermore, the results from matrigel
plug assay demonstrated that pY747 peptide resulted in inhibition
of VEGF-induced angiogenesis in wild type, but not in DiYF mice,
demonstrating the specificity of the approach (Figure 4d and 4e).
Together, these results indicate that b3CT phosphorylation at Y
747
positively regulates integrin-dependent responses in angiogenesis.
VEGF-induced VEGFR2 phosphorylation and downstream
signaling are diminished by pY747 peptide
Studies from our lab and others demonstrated cross-activation
of VEGFR2 and avb3 [16]. To test whether VEGFR2 activation
and subsequent signaling were affected by pY747 peptide, we
assessed Y
1175 phosphorylation of VEGFR2, a major VEGF-
dependent VEGFR2 autophosphorylation site implicated in EC
Table 1. Structural statistics for the 15 final NMR structures of
VpepB.
NMR distance constraints
Distance constraints
Total NOE 151
Intra-residue 48
Inter-residue 103
Sequential (|i2j|=1) 72
Medium-range (|i2j,5) 31
Long-range (|i2j|.=5) 0
Hydrogen bonds 0
Structure statistics
Violations (mean and s.d.)
Distance constraints (A ˚) 0.045+/20.007
Max. distance constraint violation (A ˚) 0.366
Deviations from idealized geometry
Bond lengths (A ˚) 0.012+/20.0001
Bond angles (u) 0.75+/20.039
Impropers (u) 0.36+/20.027
Average pairwise r.m.s. deviation (A ˚)
a ordered residues 801–804
Heavy 0.5
Backbone 0.1
Ramachandran plot
a
Most favored 51.1%
Additionally allowed 44.4%
Generously allowed 4.4%
Disallowed regions 0.0%
a)Ordered residues (residues with sum of phi and psi order parameters ,1.8) are
considered for r.m.s.d. calculations and Ramachandran statistics.
doi:10.1371/journal.pone.0031071.t001
Figure 1. Summary of the in vitro evidence for a direct interaction between VEGFR2 and b3CTs and structure of the VEGFR2
801YLSI
motif in bound conformation. Chemical shift titrations were performed in water at 25uC at pH 6.1 with b3 concentrations of in a range of 30–
100 mM. Expanded region of
15N HSQC spectra show chemical shift perturbations for a) b3NP. b) b3MP in presence of VpepA at the ratio 1:1.
c) Chemical shift changes in
15N labeled b3NP upon addition of VpepA at the ratios of 1:1 (red) and 1:2 (green). d) Chemical shift changes in
15N
labeled b3MP upon addition of VpepA at the ratios of 1:1 (red) and 1:2 (green). Delta [ppm] refers to the combined HN and N chemical shift changes
according to the equation: Dd(HN,N)=((DdHN
2+0.2(DdN)
2)
1/2, where Dd=dbound-dfree. Transferred NOEs: all the NOESY experiments were performed in
50 mM NaCl and 25 mM Na-phosphate buffer at pH 6.1 and 25uC with peptide to protein ratio of 50 to 1 and peptide concentrations of 1 mM;
e) VpepB alone is shown in black and VpepB in combination with GST-b3 is shown in green; f) VpepC alone (black) and VpepC in combination with
GST-b3 (green). g) Ribbon representation of VpepB structure. Hydrophobic residues of
801YLSI region are shown in dark gray. h) Backbone
superimposition of the 15 lowest energy conformers of VpepB. Residues used for superimposition are
801YLSI. Molecular graphics images were
produced using the UCSF Chimera package (Pettersen et al., 2004).
doi:10.1371/journal.pone.0031071.g001
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synthesis [31,32]. To this end, the phosphorylation status of Y
1175
of VEGFR2 and ERK1/2 was assessed in ECs, which were
treated with peptides with or without VEGF stimulation. Western
blot analysis shows that treatment of cells with pY747 peptide
resulted in inhibition of VEGFR2 and ERK1/2 phosphorylation
in a dose-dependent manner with the maximal effect occurring at
40 mM or higher concentrations; the control F747 peptide,
however, had no effect (Figure 5). Thus, interference with
intracellular signaling mediated by phosphorylated b3CT results
in impaired activation of VEGFR2 and proangiogenic signaling
events downstream of VEGFR2.
In contrast to VEGF, pY747 peptide had no effect on bFGF-
induced activation of downstream signaling molecules, represented
by phospho-ERK. As shown in Figure S3, ERK activation by
bFGF was not affected in the presence of either pY747 or control
F747 peptide. In these experiments, effects of VEGF were
neutralized by VEGFR inhibitor, AAL-993. Together with results
of NMR experiments (Figure 1) and previously published
observations [16,18], these data further emphasize the specificity
and importance of a cross-talk between VEGFR2 and b3 integrin.
Together, our findings provide a structural basis for the cross-talk
between b3CT and VEGFR2 and show that this cross-talk
mediates important cellular processes, such as VEGFR2 activa-
tion, EC tube formation, and angiogenesis.
Discussion
Over the last decade, the importance of the interplay between
integrins and growth factor receptors was demonstrated in a
number of physiologically important processes, including angio-
genesis. At the same time, tyrosine phosphorylation of b3 integrin
has been identified as a major regulatory event for the modulation
of this integrin function and its cross-talk with VEGF receptor. In
the presented work, we have focused on the intertwining of these
two processes. Using a NMR approach, we have documented a
direct interaction between VEGFR2 and b3 CTs, which appeared
to be dependent upon Y
747 phosphorylation of b3.
In platelets, Y
747 phosphorylation of b3 occurs as a consequence
of ligand binding and receptor clustering [33]. In this case,
tyrosine phosphorylation appears to be involved in outside-in
signaling [7,29]. In ECs, however, Y
747 phosphorylation of b3
occurs in response to VEGF stimulation in the absence of ligand.
Here, we have shown that the phosphopeptide containing pY
747
acts as an antagonist of VEGF-induced and integrin-mediated
responses. It inhibits cellular processes known to be dependent on
b3 integrin activation, such as VEGF-induced endothelial tube
formation, sprouting, and angiogenesis in vivo. Importantly, the
phosphopeptide containing pY
747 is a highly specific inhibitor for
processes dependent on b3 and its phosphorylation, since this
peptide has no effect in DiYF knock-in mice expressing mutant b3
unable to undergo phosphorylation as well as in b3 knock-out
mice.
Previous studies using cell systems with ‘‘activatable’’ aVb3, such
as myeloid K562 cells, demonstrated that that substitution of Y
747
by phenylalanine impaired agonist-induced adhesion to VN
[10,13]. A subsequent study demonstrated that firm adhesion of
K562 cells to VN proceeds through three steps, and it is the second
step characterized by a four-fold increase in receptor-ligand binding
strength that was shown to be dependent on phosphorylation of
Y
747. In ECs, DiYF mutations of both Y
747 and Y
759 to
phenylalanines affected VEGF-induced activation of aVb3 and
endothelial responses [16]. However, in Chinese hamster ovary
(CHO) cells, expressing aVb3, a cell model generally characterized
by the lack of inside-out integrin signaling, the Y
747F mutation did
not affect binding of fibrinogen-coated beads [33]. A possibility of
indirect inhibitory effect of b3 phosphorylation was reported in a
study utilizing expression of temperature-sensitive v-Src in osteo-
sarcoma cells. In this study, increased b3 phosphorylationcorrelated
with reduced aVb3-fibronectin binding strength, which was rescued
by the Y
747F mutation [14]. However, many mutagenesis studies
using a well-defined integrin activation monitoring system, i.e.
binding of soluble monovalent ligand, demonstrate that mutations
of Y
747 to F generally diminish integrin function. This effect might
also be attributed to the disruption of binding sites for key integrin
activators,such astalinand kindlin.In this regard, ourdata showing
differential effects of b3 phosphopeptide containing pY
747 versus its
unphosphorylated form are crucial in demonstrating the role of
phosphorylation of this integrin, per se. Of particular interest is the
fact that the effect of phosphorylation may differ for other
subfamilies of b integrins. For example, in mice whose tyrosines
of the b1 tail were mutated to phenylalanines (YY
783/795FF), no
obvious defects have been observed [34]. Again, use of the Y to F
mutations need to be interpreted with an understanding that these
mutations might affect events other than the direct consequences of
phosphorylation. These reservations concerning mutagenesis stud-
ies emphasize the importance of the structural analysis presented in
this study, which allowed direct comparison of phosphorylated
versus unphosphorylated form of b3.
Y
747 phosphorylation in b3CT appears to promote a complex
formation with VEGFR2, and this complex is not present in DiYF
mutant cells [18]. Our data show not only the presence of the b3-
VEGFR2-CTs complex, but also the key regulatory role of the
Y
747 phosphorylation site in this complex formation. Furthermore,
b3CT-derived Y
747-phosphorylated peptide was able to disrupt
VEGF-induced signaling, EC tube formation, and angiogenesis, in
contrast to the unphosphorylated control. Thus, our in vitro data
supports in vivo observations that b3CT phosphorylation is crucial
for the interaction and cross-talk with VEGFR2 [16,18]. This
interaction performs a key regulatory function in pathological
angiogenesis [18], and new structural insights into this mechanism
may permit the design of novel anti-angiogenic compounds. While
we demonstrate that phosphorylation of the Y
747 likely increases
the affinity of b3 for VEGFR2-derived, membrane-proximal
peptides, additional phosphorylation of Y
759 might diminish this
effect (data not shown). This finding may indicate a key role for the
Figure 2. The pY747 peptide inhibits VEGFR2-induced angiogenesis in vitro.a ) The amino acid sequences of VpepA, human integrin b3
cytoplasmic tail (CT), and derived peptides. The conserved YLSI (VpepA), HDRKE (Integrin b3CT) along with the two tyrosine phosphorylation motifs
are shown in orange. HIV-TAT leader sequence (shown in blue) was added to allow delivery of the peptides across the cell membrane.
b) Representative images of HUVEC tube formation in the presence with or without VEGF (20 ng/mL). c) Example images of inhibition of in vitro
endothelial tube formation by the pY747 peptide. HUVEC were plated on matrigel-coated 48 well plates in the presence of 20 ng/mL VEGF and
peptides at indicated concentrations. The cells were allowed to form tubes for 16 hours, bright field images at 2.56magnification were taken and
analyzed (using computer algorithms) for number, length, and thickness of branches. d) Quantitative result of branch thickness under different
treatments. e) Representative images of tube formation in the presence of pY747 and pY759 peptide. f) Quantitative result of tube length as
indicated.
doi:10.1371/journal.pone.0031071.g002
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31071Figure 3. The pY747 peptide inhibits VEGFR2-induced angiogenesis in ex vivo and in vivo.a ) Inhibition of ex vivo endothelial sprouting by
the pY747 peptide. Mouse aortic rings were embedded in matrigel in the presence or absence of 40 ng/mL of VEGF and peptides as indicated.
Photographs were taken at three days and the number of endothelial sprouts originating from each ring was determined. b) Quantification of aortic
ring assay as indicated in Fig. 3a. c) Inhibition of in vivo angiogenesis by pY747 peptide. Results of matrigel plug angiogenesis assay are shown. The
indicated peptides at 200 mM concentration were mixed with growth factor-reduced matrigel containing VEGF (500 ng/mL) and injected
subcutaneously into wild type mice. Seven days later, the matrigel implants were removed, sectioned, and blood vessels were stained with CD31 Ab
(red) and nuclei with DAPI (blue). Vessel area was determined using ImagePro. d) Quantified results of matrigel plug assay as indicated in Fig. 3c.
doi:10.1371/journal.pone.0031071.g003
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2/2 or DiYF mice. a) pY747 peptide does not inhibit VEGF-induced aortic ring growth from
b3
2/2 mice. Mouse aortic rings were embedded in matrigel in the presence of 40 ng/mL of VEGF and 40 mM of peptides as indicated.
b) Quantification of aortic ring assay as indicated in Fig. 4a. c) pY747 could not inhibit bFGF-induced aortic ring growth, Mouse aortic rings were
isolated from wild type (WT), b3
2/2, and DiYF mice and embedded in matrigel in the presence of 40 ng/mL of VEGF, 20 ng/mL of bFGF or pY747
peptides as indicated. Aortic rings were incubated for 3 days for wild type and b3
2/2 aortic rings and 4 days for DiYF aortic rings (longer incubation
was used to obtain visible aortic sprouting which is diminished in these mice). d) pY747 peptide does not inhibit angiogenesis in DiYF mice. Peptides’
effect on in vivo angiogenesis in wild type mice and DiYF mice was tested as described. e) Quantification of blood vessels in matrigel plus assay as
indicated.
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747 motif in positive regulation of the cross-talk between
VEGFR2 and b3 [30], which is in agreement with differences in
the kinetics of Y
747 vs. Y
759 phosphorylation in response to VEGF
in ECs [18].
To conclude, we have shown direct complex formation between
cytoplasmic tails of b3 integrin and VEGFR2 in vitro, structurally
characterized one of the VEGFR2 binding motifs, and confirmed
that the above interaction is further enhanced by Y
747 phosphor-
ylation of b3 integrin. We also showed in vivo that pY
747 affects b3
integrin cross-talk with VEGFR2 resulting in suppressed VEGF-
induced signaling, endothelial tube formation, and angiogenesis.
These findings identify important regulatory elements controlling
the activity of b3 integrins in ECs, which underlie a number of
more complex responses, including thrombosis/haemostasis and
pathological angiogenesis.
Materials and Methods
Peptide synthesis
Short peptides corresponding to the membrane proximal region
of VEGFR2, VpepA (
786LRTVKRANGGELKTGYLSIVMDP-
DELPLDE
815), VpepB (
786LRTVKRANGGELKTGYLSIV
805),
VpepC (
791RANGGELKTGYLSIVMDPD
809), and membrane-
permeable corresponding to b3CT peptides, pY
747(YGRKKRR-
QRRRDTANNPLpYKEATSTFT),Y
747 (YGRKKRRQRRRD-
TANNPLYKEATSTFT), and F
747 (YGRKKRRQRRRDTAN-
NPLFKEATSTFT) were synthesized in the Cleveland Clinic
Molecular Biotechnology Core laboratory byFmoc chemistry
using solid phase Omega 396 synthesizer (Advanced ChemTech,
Louisville, KY). Quality analysis of the peptides was performed by
HPLC on an analytical reverse phase C-18 column and by matrix
Figure 5. pY747 peptide inhibits VEGF-induced VEGFR2 phosphorylation and ERK activation. Serum starved HUVEC were incubated
with the indicated concentrations of pY747 or F747 peptides for 3 h, then stimulated with 20 ng/mL VEGF for five min at 37uC or left unstimulated.
The cells were lysed and equal amounts of protein from total cell lysates were subjected to Western blot analysis with a) anti-p-VEGFR2 (Y1775) Ab or
b) anti-p-ERK1/2 antibodies. The blots were reprobed with a) anti-total VEGFR2 or b) anti-total ERK1/2 antibodies as loading control. Bands were
quantified by densitometric analysis and fold increase over unstimulated cells are displayed (right panels).
doi:10.1371/journal.pone.0031071.g005
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mass spectrometry (MS).
Expression and Purification
Cloning, expression, and purification of b3CT and GST-b3
have been described previously [5,35]. To produce
15N isotopi-
cally labeled b3CT cells were grown in M9 minimal medium
containing
15NH4Cl (1.1 g/L). Tyrosine phosphorylation of b3CT
has been achieved in vivo by using TKB1 bacterial cell line from
Stratagene following the manufacture’s protocol for the recombi-
nant protein induction as described elsewhere [26].
NMR Spectroscopy
1H-
15N Heteronuclear single quantum correlation (HSQC)
titration experiments were performed in water at 25uC on Varian
Inova 600 MHz equipped with inverse-triple resonance cryo-
probe. Chemical shifts assignments have been determined
previously [5] and have been modified to address the effect of
phosphorylation. Transferred NOESY experiments for different
peptides were performed at pH 6.1. Different ratios of the peptides
to the binding partner were investigated to find the optimal range
for NOE transfer for each particular analysis. All the spectra were
processed with NMRPipe [36] and analyzed by CCPN software
suite [37]. The resonance assignments of unlabeled peptides were
made using conventional 2D
1H-
1H TOCSY and NOESY spectra
[38] by CCPN software suite [37].
Structure Calculation
Sequence-specific assignments of integrin tails are described
elsewhere [5]. Restraints from two dimensional
1H-
1H NOESY
experiment were used for the structure calculations. The structures
were calculated based on the hybrid distance geometry-dynamical
simulated annealing method using the X-PLOR-NIH [39]. The
target function minimized during simulated annealing (as well as
during conventional Powell minimization) comprises only qua-
dratic harmonic terms for covalent geometry, square-well
quadratic potentials for the experimental distance restraints. Best
structures from the ensembles have been chosen based upon
lowest Lennard–Jones potential. None of the structures have NOE
violations greater than 0.5 A ˚. The Protein Structure Software suite
(PSVS; courtesy of CABM Structural Bioinformatics Laboratory,
Rutgers State University of New Jersey) was used for structure
validation (http://psvs-1_3.nesg.org/).
Materials and Animals
Rabbit polyclonal anti-VEGFR2, anti-b3-integrin, and mouse
monoclonal anti-phospho tyrosine antibodies were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-
ERK1/2, Anti-p-ERK1/2, and anti-phospho-VEGFR2 were
from Cell Signaling Technology (Beverly, MA). VEGF was
purchased from R&D Systems (Minneapolis, MN) and matrigel
was obtained from BD Biosciences (San Jose, CA). DiI was
obtained from Invitrogen (Carlsbad, CA). Drabkin’s reagent was
from Sigma. C57BL/6 (wild type), b3 knock-out (C57BL/6
background), and DiYF knock-in (in DiYF mice, the b3 integrin
tyrosines 747 and 759 are mutated to phenylalanine, C57BL/6
background [29]) mice were housed and treated according to
Cleveland Clinic Institutional Animal Care and Use Committee
regulations.
Cell culture
Human umbilical cord vein endothelial cells (HUVEC) were
grown in DMEM:F12 media supplemented with 15% FBS,
100 U/mL penicillin, 100 mg/mL streptomycin, 90 mg/mL hep-
arin sulfate, and 90 mg/mL endothelial cell growth factor. Lung
ECs: Mouse lungs were excised, minced, and digested using a
collagenase-dispase reagent (Roche Diagnostics, Indianapolis, IN).
Digests were strained and the resulting cell suspension was plated
on flasks coated with 10 mg/mL fibronectin in HUVEC growth
media.
Aortic ring, tube formation, and in vivo Matrigel
angiogenesis assays
The aortic ring assays were performed as described previously
[18].
The formation of vascular tube-like structures by HUVEC was
performed as described previously [40] with modification. We
coated 48-well plates with 200 mL of growth-factor reduced
Matrigel according to the manufacturer’s instructions. HUVECs
were starved 3 h in DMEM:F12, 1% FBS, and 90 mg/mL
heparin. The cells were collected by trypsinization, suspended in
starvation media, and 60,000 cells were plated per well in the
presence or absence of the indicated peptides or VEGF at the
indicated concentrations. 16 h later, the cells were washed 26in
PBS, fixed with 2% formaldehyde, and bright field images of the
wells were taken.
Matrigel angiogenesis assays were done as described [41].
Growth factor-reduced matrigel was mixed with 500 ng/mL
VEGF and 200 mM of peptides, and 400 mL injected into mice
subcutaneously. At seven days, the matrigel implants were
surgically removed in OCT freezing medium and 7 mm thick
sections were prepared. Sections were fixed with 4% paraformal-
dehyde, incubated with Rat anti-mouse CD31 (BioLegend), and
exposed to anti-rat Alexa Fluor568 (Invitrogen). The slides were
mounted with medium (DakoCytomation) and images were taken
by a TCS-SP (Leica) microscope. For quantification, the images
were analyzed with ImagePro software (Media Cybernetics).
Immunocytochemistry Analysis
HUVEC were grown in monolayer on glass slides and then
treated with fluorescein-labeled peptides for the indicated time
periods. The cells were further stained with the lipophilic tracer
DiI to stain the cell membrane following the manufacturer’s
instructions, then fixed with 2% paraformaldehyde for 10 min,
washed, mounted with cover slips, and analyzed by confocal
microscopy (Leica).
Tube Formation Analysis
Network analysis of tube forming HUVEC was performed in an
automated fashion using customized visual basic macros devel-
oped within Image-Pro Plus (v6.2, Media Cybernetics, Silver
Spring, MD). Bright-field images were imported into Image-Pro
one-by-one, in batch mode. A high-pass spectral filter was applied
to each image to enhance/equalize intensity; enabling application
of a fixed threshold to segment the cell network (will be referred to
as the ‘‘tube mask’’). Since branches were sometimes thin (1 pixel
thick), node to node branches were often disconnected following
segmentation, even though visual observation confirmed continu-
ity. To resolve this issue, a second approach was applied to
preserve continuity. A top-hat morphological filter was applied to
the original image to enhance the appearance of low intensity
signal, and segmented using a fixed intensity and area threshold.
This image was then ‘‘added’’ to the tube mask and inverted
(intensity across the tube, referred as ‘‘lumens of each tube,’’ was
converted to 255). Using Euclidean distance map (EDM)-based
background clustering, the lumen of each tube was segmented
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then inverted and ‘‘skeletonized’’ to create continuous single pixel-
width medial lines along the entire tube network. To avoid errors
due to the ‘‘skeletonization’’ process, an additional algorithm was
applied to cluster nodes that were within a given distance (pre-
determined value confirmed visually). These nodes were then
classified as 32,4 2,o r5 + branch nodes and summed for each
category for output to Microsoft Excel. In addition to incorrect
node classification, the skeletonization process can also produce
spurious branches. To eliminate these, a ‘‘pruning’’ filter was
applied to remove branches of a predefined length connected to a
single node. The total number of branches was then summed and
exported to Excel. To determine mean node and branch thickness,
a Euclidean distance map was generated from the tube mask and
‘‘multiplied’’ by the node and skeletal branch masks respectively.
Thickness values were calculated by summing the resulting pixels
values in each of these images, multiplying these values by a factor
of two and then by the pixel resolution, and lastly dividing by the
total number of node pixels or skeletal branch pixels.
Statistical analysis
Values were expressed as mean plus or minus standard
deviations (SD). P values were based on the paired t-test. All the
experiments were repeated at least three or more times. Results
were considered statically significant with P value less than 0.05.
Supporting Information
Figure S1 Sequential connectivity map for VpepB.
Figure is produced by CCPN Analysis 2.1.1.
(JPG)
Figure S2 Uptake of b3CT derived peptides by EC.
Peptides were labeled with fluorescein (green) at the N-
termini and added to HUVEC growth media for the
indicated times. The plasma membranes were labeled with Dil
(red) and nuclei stained with DAPI (blue). The cells were fixed and
analyzed by confocal microscopy.
(JPG)
Figure S3 bFGF induced signaling events are not
affected by F747 or pY747 peptides. HUVEC cells
pretreated with peptides as indicated and stimulated with bFGF
for 30 min. Total cell lysates were immuno-probed with anti
phospho-erk antibodies.
(JPG)
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